Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARDS 5: Insulin Icodec vs Daily Basal Insulins in Type 2 Diabetes
NCT04760626Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2021
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of insulin icodec in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Mar 2021; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04760626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04760626.